Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
PURPOSE: To describe healthcare professional (HCP) and patient time and related costs associated with trastuzumab intravenous infusion (IV) and trastuzumab subcutaneous (SC) formulations in patients with HER2-positive early breast cancer. METHODS: This prospective, observational time, and motion study in three Spanish centers was run as a substudy of the PrefHer trial. We recorded active HCP time for trastuzumab SC and IV-related tasks and calculated HCP time as the mean sum of task times over 154 administrations (80 IV, 74 SC). We calculated mean patient infusion chair time and treatment room time. Staff costs were calculated using fully loaded salary costs based on Spanish salaries (€ 2012). RESULTS: The transition from trastuzumab IV to SC led to a 50% reduction in active HCP time [27.2 min (95% CI 21.8-32.6) vs. 13.2 min (95% CI 8.9-17.5) per cycle]. Time savings resulted from avoiding IV catheter installation and removal, line flushing, and drug reconstitution. SC administration led to a fivefold reduction (78-85%) in chair time and a fourfold reduction (59-81%) in patient treatment room time, resulting in 24 h free-up time in the total treatment course (18 cycles). Total estimated direct costs were € 29,431.75 and € 28,452.12 for IV and SC, respectively, a saving of € 979.60 over a full treatment course. CONCLUSIONS: Trastuzumab SC provided substantial time savings for HCP and patients, and reduced staff costs vs. trastuzumab IV. Reducing the use of hospital facilities may result in further savings and improved quality of medical care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on direct measurements, active HCP time was 13–92 min (IV) versus 7–30 min (SC); a difference of 6–62 min [50, 53, 59, 62–65, 67].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the five publications reporting total costs including indirect costs, indirect costs were lower for patients who received SC versus IV trastuzumab [51, 59, 63, 64, 71].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [59]
In the citing paper
“Total time spent at the hospital was also reported, ranging from 3–7 h (IV) to 1–5 h (SC), with a difference of 1.5–2 h [59, 64, 67].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351 · cited 1×
“positive breast cancer, the SC formulation demonstrated pharmacokinetics, efficacy, and a safety profile comparable to IV, with an administration time of\5 min [2].”
BackgroundPivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Self-citationDe Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016) · Cancer Medicine · doi:10.1002/cam4.573 · Cited by 112
Shapiro, C. L., Moriarty, J. P., Dusetzina, S. B., Himelstein, A. L., Foster, J. C., Grubbs, S. S., Novotny, P. J., & Borah, B. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7437 · Cited by 78
Burcombe, R., Chan, S., Simcock, R., Samanta, K., Percival, F., & Barrett-Lee, P. (2013) · Advances in Breast Cancer Research · doi:10.4236/abcr.2013.24022 · Cited by 59
Jackisch, C., Müller, V., Dall, P., Neumeister, R., Park-Simon, T.-W., Ruf-Dördelmann, A., Seiler, S., Tesch, H., & Ataseven, B. (2015) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0035-1546172 · Cited by 42
Ryan, S., North, R., Harvey, V., & Cox, L. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s85599 · Cited by 39
Shinder, G. A., Paradis, P. E., Posman, M., Mishagina, N., Guay, M., Linardos, D., & Batist, G. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-370 · Cited by 23
Papadmitriou, K., Trinh, X. B., Altıntaş, S., Pa, V. D., Mt, H., & Wa, T. (2015) · PubMed Central · Cited by 21
Colombo, A., Solberg, B. C. J., Vanderhoeft, E., et al. (2005) · Cancer Nursing · doi:10.1097/00002820-200511000-00011 · Cited by 20
Cited by
Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A. (2019) · Future Oncology · doi:10.2217/fon-2019-0368 · Cited by 69
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Felip, E., Rojas, C. I., Schenker, M., Kowalski, D. M., Casarini, I. A., Csöszi, T., Şendur, M. A. N., Martins, J., Calles Blanco, A., Wang, C.-C., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.012 · Cited by 40
O'Brien, G. L., O'Mahony, C., Cooke, K., Kinneally, A., Sinnott, S.-J., Walshe, V., Mulcahy, M., & Byrne, S. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.01.011 · Cited by 29
Rojas, L., Muñiz, S., Medina, L., Peña, J., Acevedo, F., Pinto, M. P., & Sanchez, C. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227961 · Cited by 23
“60 (USD $1,156) savings per patient versus IV-TZM; however, they did not assess costs associated with serious ADRs, and the criteria used to define patient weights for the calculation of load and maintenance doses were not reported [20].”
Background
Metadata
- Authors
- Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., & De la Haba-Rodríguez, J.
- Affiliations
- Hospital Universitario de Valme (ES)
- Hospital Universitario de Getafe (ES)
- Roche (Spain) (ES)
- Corresponding author
- Navarro, B.
- ORCID
- Venue
- Clinical and Translational Oncology
- Published
- 2017-06-02
- Volume
- 19
- Issue
- 12
- Pages
- 1454-1461
- ISSN
- 1699-048X (ISSN-L)
- 1699-3055
- PMC
- PMC5700215
- OpenAlex
- W2621391008
- Cited by
- 54
- References
- 19
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 11 · 2023: 10 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 6 · 2018: 1 · 2017: 1
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Clinical & Translational Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- Roche Pharma
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- trastuzumab, HER2-positive breast cancer, subcutaneous administration, intravenous infusion, cost minimization, personnel costs, time and motion study, early breast cancer
- MeSH terms
- Trastuzumab, Antineoplastic Agents, Breast Neoplasms, Costs and Cost Analysis, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Middle Aged, Prognosis, Prospective Studies, Spain, Erb-b2 Receptor Tyrosine Kinases, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. https://app.cochat.ai/papers/10.1007/s12094-017-1684-4
- The paper
- Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., & De la Haba-Rodríguez, J. (2017). Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-017-1684-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.